MyoKardia, Inc. (NASDAQ:MYOK) was downgraded by research analysts at TheStreet from a “c” rating to a “d+” rating in a research report issued on Friday.

Several other research firms have also recently issued reports on MYOK. Credit Suisse Group reiterated an “outperform” rating and issued a $55.00 target price (up from $45.00) on shares of MyoKardia in a research note on Tuesday, September 19th. Zacks Investment Research cut shares of MyoKardia from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. ValuEngine upgraded shares of MyoKardia from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Wedbush reiterated an “outperform” rating and issued a $51.00 target price on shares of MyoKardia in a research note on Wednesday, September 20th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $65.00 target price (up from $45.00) on shares of MyoKardia in a research note on Monday, August 21st. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $55.00.

Shares of MyoKardia (NASDAQ MYOK) traded down $1.50 during trading on Friday, reaching $40.70. 276,775 shares of the company were exchanged, compared to its average volume of 424,305. MyoKardia has a 12 month low of $10.55 and a 12 month high of $49.55.

MyoKardia (NASDAQ:MYOK) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.42). MyoKardia had a negative net margin of 53.49% and a negative return on equity of 18.01%. The firm had revenue of $5.63 million during the quarter, compared to analysts’ expectations of $6.10 million. During the same period in the previous year, the business posted ($0.35) EPS. The business’s revenue was up 58.6% compared to the same quarter last year. equities analysts expect that MyoKardia will post -1.6 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “MyoKardia, Inc. (MYOK) Stock Rating Lowered by TheStreet” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/myokardia-inc-myok-stock-rating-lowered-by-thestreet/1685911.html.

In other MyoKardia news, major shareholder Rock Ventures Ii L.P. Third sold 221,250 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $41.30, for a total transaction of $9,137,625.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Sanofi acquired 350,000 shares of MyoKardia stock in a transaction on Monday, August 14th. The shares were bought at an average price of $35.50 per share, with a total value of $12,425,000.00. The disclosure for this purchase can be found here. Insiders have sold 1,719,213 shares of company stock valued at $72,930,579 over the last 90 days. 33.40% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of MyoKardia by 11.5% during the second quarter. Vanguard Group Inc. now owns 764,919 shares of the biotechnology company’s stock worth $10,020,000 after buying an additional 78,800 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of MyoKardia by 103.5% during the second quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock worth $6,243,000 after buying an additional 242,408 shares in the last quarter. State Street Corp grew its holdings in shares of MyoKardia by 17.4% during the second quarter. State Street Corp now owns 232,581 shares of the biotechnology company’s stock worth $3,048,000 after buying an additional 34,533 shares in the last quarter. Northern Trust Corp grew its holdings in shares of MyoKardia by 31.9% during the second quarter. Northern Trust Corp now owns 202,983 shares of the biotechnology company’s stock worth $2,658,000 after buying an additional 49,044 shares in the last quarter. Finally, Marshall Wace North America L.P. grew its holdings in shares of MyoKardia by 28.0% during the second quarter. Marshall Wace North America L.P. now owns 155,274 shares of the biotechnology company’s stock worth $2,019,000 after buying an additional 33,970 shares in the last quarter. 43.67% of the stock is owned by institutional investors and hedge funds.

MyoKardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Analyst Recommendations for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.